A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Trimodulin (Primary)
- Indications Community-acquired pneumonia; COVID 2019 infections; COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms TRICOVID
- Sponsors Biotest AG; Biotest Pharmaceuticals
- 03 Apr 2024 This trial has been Discontinued in Spain, according to European Clinical Trials Database.
- 12 Dec 2023 According to a Biotest Pharmaceuticals media release, trial has now been opened for enrolment of patients with CAP caused by any type of pathogen.
- 12 Dec 2023 According to a Biotest Pharmaceuticals media release, first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated .